Study details
Enrolling now
Mechanistic Studies of Psilocybin in Headache Disorders
Yale University
NCT IDNCT06464367ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
50
Study length
about 1.6 years
Ages
21–70
Locations
1 site in CT
About this study
This trial is testing whether psilocybin affects the brain and body in people with migraine. Researchers will measure changes in brain activity, inflammation markers, sleep patterns, and circadian rhythms before and after taking psilocybin or a placebo.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Psilocybin
PhaseEARLY_Phase 1
DrugPsilocybin
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
oral
Endpoints
Secondary: Adverse events, Change in IL-6
Body systems
Neurology